Grufity logoGrufity logo
Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
RZLT

RZLT - Rezolute, Inc. Stock Price, Fair Value and News

4.66USD-0.02 (-0.43%)Market Closed

Market Summary

RZLT
USD4.66-0.02
Market Closed
-0.43%

RZLT Alerts

  • 1 major insider buys recently.

RZLT Stock Price

View Fullscreen

RZLT RSI Chart

RZLT Valuation

Market Cap

187.0M

Price/Earnings (Trailing)

-3.21

Price/Sales (Trailing)

35.26

Price/Free Cashflow

-3.72

RZLT Price/Sales (Trailing)

RZLT Profitability

Return on Equity

-82.17%

Return on Assets

-66.36%

Free Cashflow Yield

-26.85%

RZLT Fundamentals

RZLT Revenue

Revenue (TTM)

5.3M

Rev. Growth (Yr)

-24.39%

Rev. Growth (Qtr)

-13.89%

RZLT Earnings

Earnings (TTM)

-58.2M

Earnings Growth (Yr)

-8.79%

Earnings Growth (Qtr)

-22.58%

Breaking Down RZLT Revenue

Last 7 days

3.1%

Last 30 days

16.5%

Last 90 days

75.2%

Trailing 12 Months

157.5%

How does RZLT drawdown profile look like?

RZLT Financial Health

Current Ratio

11.82

Debt/Equity

0.2

Debt/Cashflow

-3.52

RZLT Investor Care

Shares Dilution (1Y)

8.98%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20245.3M000
20232.8M4.2M5.2M5.7M
202275.0K81.0K480.0K1.3M
2021725.0K63.0K069.0K
20201.7M1.2M1.2M1.4M
2019745.3K1.3M1.6M1.7M
20181.2M762.0K660.3K532.5K
2017661.1K1.1M1.2M1.3M
2016495.6K442.0K466.1K489.8K
2015682.7K539.5K378.0K461.1K
2014502.2K684.1K886.4K838.7K
2013565.4K634.1K597.8K540.1K
2012261.7K0362.9K464.2K
2011000160.5K
Get all data in R, Python etc through our Historical Stock Data APIs

About Rezolute, Inc.

RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
 CEO
 WEBSITErezolutebio.com
 INDUSTRYBiotechnology
 EMPLOYEES47

Rezolute, Inc. Frequently Asked Questions

What is the ticker symbol for Rezolute, Inc.? What does RZLT stand for in stocks?

RZLT is the stock ticker symbol of Rezolute, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rezolute, Inc. (RZLT)?

As of Fri Jul 26 2024, market cap of Rezolute, Inc. is 187.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RZLT stock?

You can check RZLT's fair value in chart for subscribers.

Is Rezolute, Inc. a good stock to buy?

The fair value guage provides a quick view whether RZLT is over valued or under valued. Whether Rezolute, Inc. is cheap or expensive depends on the assumptions which impact Rezolute, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RZLT.

What is Rezolute, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, RZLT's PE ratio (Price to Earnings) is -3.21 and Price to Sales (PS) ratio is 35.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RZLT PE ratio will change depending on the future growth rate expectations of investors.